IL1B and ganglioneuroma: Compared to the controls, GN treatment increased the IL-1β levels in the kidney homogenate and serum (177.1 ± 25.5 pg/mL vs. 144.7 ± 25.5 pg/mL, p < 0.05) and (174.3 ± 35.9 pg/mL vs. 140.5 ± 31.6 pg/mL, p < 0.05).